Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium

International Journal of Gynecological Pathology

Volumn 30, Issue 5, 2011, Pages 484-491

  Stewart, Colin J R ^a   Crook, Maxine L ^a   Lacey, Joanne ^a   Louwen, Kathryn ^a  

^a King Edward Memorial Hospital   (United States)

Author keywords

Carcinoma; Cytokeratin 19; Endometrium; Invasion; MELF

Indexed keywords

CYTOKERATIN 19;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR CELL; UTERINE CERVIX CARCINOMA IN SITU;

CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80051795086     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3182158944     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491-505.
3. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111:436-7.
4. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002;110:673-89.
5. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004;35:649-62.
6. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009;105:103-4.
7. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: A review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2002;9:145-84.
8. Ambros RA, Ballouk F, Malfetano JH, et al. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am J Surg Pathol 1994;18:569-75.
9. Longacre T, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: An adenoma malignum pattern of myoinvasion. Am J Surg Pathol 1999;23:69-78.
10. Landry D, Mai KT, Senterman MK, et al. Endometrioid adenocarcinoma of the uterus with a minimal deviation invasive pattern. Histopathology 2003;42:77-82.
11. Kalyanasundaram K, Ganesan R, Perunovic B, et al. Diffusely infiltrating endometrial carcinomas with no stromal response: Report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol 2010;18:138-43.
12. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: A study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 2003;22:324-33.
13. Stewart CJR, Brennan BA, Leung YC, et al. MELF pattern invasion in endometrial carcinoma: Association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009;41:471-6.
14. Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 2007; 26:115-23.
15. Shia J, Black D, Hummer AJ, et al. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol 2008;39:116-25.
16. Stewart CJR, Crook ML, Leung YC, et al. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: Variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod Pathol 2009;22:725-33.
17. Stewart CJR, Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: Evidence for epithelial-mesenchymal transition. Histopathology 2009; 55:91-101.
18. Stewart CJR, Crook ML, Manso L. Fascin expression in lowgrade uterine endometrioid adenocarcinoma; correlation with MELF type alteration at the deep invasive margin. Histopathology. In press.
19. Stewart CJR, Crook ML, Doherty DA. Micro-anatomical variation in cellular proliferation in endometrial adenocarcinoma, and inverse correlation between Ki-67 and cytokeratin 7 expression. Histopathology 2010;57:46-54.
20. Stewart CJR, Crook ML. Galectin-3 expression in uterine endometrioid adenocarcinoma; comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion. Int J Gynecol Pathol 2010;29:555-61.
21. Stewart CJR, Crook ML. CD147 (EMMPRIN) and matrix metalloproteinase-2 expression in uterine endometrioid adenocarcinoma. Pathol Res Pract 2011;207:30-6.
22. Bartek J, Bartkova J, Taylor-Papadimitriou J, et al. Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J 1986;18:565-75.
23. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-39.
24. Kwaspen FHL, Smedts FMM, Broos A, et al. Reproducible and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology 1997;31:503-16.
25. Jain R, Fischer S, Serra S, et al. The use of cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol 2010;18:9-15.
26. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001; 14:338-42.
27. De Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005;47:391-401.
28. Zhuang P-Y, Zhang J-B, Zhu X-D, et al. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 2008;112:2740-8.
29. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: A possible progenitor cell origin. Histopathology 2006;49:138-51.
30. Yoneda N, Sato Y, Kitao A, et al. Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest. doi:10.1038/labinvest.2010.161.
31. Schmitt AM, Aniauf M, Rousson V, et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007;31:1677-82.
32. Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 2004;28:1145-53.
33. Zhang X, Chen SB, Chen JX, et al. CK19 mRNA expression in the bone marrow of patients with esophageal squamous cell carcinoma and its clinical significance. Dis Esophagus 2010; 23:437-43.
34. Saloustros E, Mavroudis D. Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. Future Oncol 2010;6:209-19.
35. Uen YH, Lu CY, Tsai HL, et al. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative surgery. Ann Surg Oncol 2008;15:2120-8.
36. Yuan CC, Wang PH, Ng HT, et al. Detecting cytokeratin 19 mRNA in the peripheral blood cells of cervical cancer patients and its clinical-pathological correlation. Gynecol Oncol 2002;85:148-53.
37. Ji XQ, Sato H, Tanaka H, et al. Real-time quantitative RTPCR detection of disseminated endometrial tumor cells in peripheral blood and lymph nodes using the LightCycler system. Gynecol Oncol 2006;100:355-60.
38. Petersen OW, Gudjonsson T, Villadsen R, et al. Epithelial progenitor cell lines as models of normal breast morphogenesis and neoplasia. Cell Prolif 2003;36(suppl 1):33-44.
39. Adegboyega PA, Qiu S. Immunohistochemical profiling of cytokeratin expression by endometrial stroma sarcoma. Hum Pathol 2008;39:1459-64.
40. Pavlakis K, Messini I, Panoskaltsis T, et al. MELF invasion in endometrial cancer as a risk factor for lymph node metastasis. Histopathology. DOI:10.1111/j.1365-2559.2011.03802.x.
41. Hendrix MJ, Seftor EA, Chu YW, et al. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 1996;15:507-25.
42. Eriksson JE, Dechat T, Grin B, et al. Introducing intermediate filaments: From discovery to disease. J Clin Invest 2009; 119:1763-71.
43. Kim S, Coulombe PA. Intermediate filament scaffolds fulfil mechanical, organizational, and signalling functions in the cytoplasm. Genes Dev 2007;21:1581-97.
44. Ding S-J, Li Y, Tan Y-X, et al. From proteomic analysis to clinical significance. Overexpression of cytokeratin 19 correlates with hepatocelullar carcinoma metastasis. Mol Cell Proteomics 2004;3:73-81.